HOME › DRUGS › DATOPOTAMAB DERUXTECAN
ACTIVE SUBSTANCE / INN

DATOPOTAMAB DERUXTECAN

Brand name(s): Datopotamab deruxtecan Daiichi Sankyo, Datroway
EMA LISTED
APPLICATION WITHDRAWN
AUTHORISED
Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
ACTIVE SUBSTANCE
Datopotamab Deruxtecan
REGULATORS
EMA
SPONSORS / MAH
Daiichi Sankyo Europe GmbH
TOTAL APPLICATIONS
2
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
DatrowayDaiichi Sankyo Europe GmbHAuthorised04/04/2025Breast Neoplasms
Datopotamab deruxtecan Daiichi SankyoDaiichi Sankyo Europe GmbHApplication withdrawnCarcinoma, Non-Small-Cell Lung

FULL INTELLIGENCE ON DATOPOTAMAB DERUXTECAN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →